Thus, our findings indicate that everolimus, an mTOR inhibitor, which has been used for treating patients with rare pituitary carcinomas (46–48), may represent an effective therapy for the >10% of prolactinomas that are resistant to dopamine agonist therapy (49,50). The gene discussed is MTOR; the disease is pituitary adenocarcinoma.